Ahmedabad-based Cadila Pharmaceuticals has entered into a strategic partnership with Sweden's NovaSAID AB to develop new treatments for inflammation and pain in conditions such as rheumatoid arthritis.
The companies will collaborate around preclinical and clinical development of drug candidates that have been developed by NovaSAID and the development will be conducted at Cadila Pharmaceuticals' facility in Ahmedabad, stated an official release from Cadila on Monday.
According to the agreement, all revenue generated from the sale and marketing in India, Middle East and Africa of products covered by the agreement will be retained by Cadila and net sales in all other countries will be shared by the two companies. Cadila will bear all costs associated with the program through to Phase II, the release added.
Speaking on this new initiative, Dr Rajiv I Modi, CMD, Cadila Pharmaceuticals said, "We have entered this partnership combining scientific expertise of NovaSAID and our drug development capabilities to work towards novel solutions in treatment of pain and inflammation, which is one of the largest therapy areas."